High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$15K
$15,639
Total Sells (Filtered)
$44.9M
$44,866,486
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Director
Other
|
2026-03-09 | $513,118 | X | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kastelein Johannes Jacob Pieter
• Officer • Chief Scientific Officer
10b5-1 SellΔOwn -59.4%
2026-03-09
$3,071,679Large
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Scientific Officer
10b5-1 SellΔOwn -59.4%
|
2026-03-09 | $3,071,679Large | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Director
Discretionary Sell
|
2026-03-06 | $828,950 | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kastelein Johannes Jacob Pieter
• Officer • Chief Scientific Officer
10b5-1 SellΔOwn -57.6%
2026-03-06
$2,853,840Large
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Scientific Officer
10b5-1 SellΔOwn -57.6%
|
2026-03-06 | $2,853,840Large | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kastelein Johannes Jacob Pieter
• Officer • Chief Scientific Officer
10b5-1 SellΔOwn -60.1%
2026-03-05
$3,165,350Large
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Scientific Officer
10b5-1 SellΔOwn -60.1%
|
2026-03-05 | $3,165,350Large | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Davidson Michael H.
• CEO
Discretionary SellΔOwn -71.8%
2026-03-02
$14,753,258MEGA
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
Discretionary SellΔOwn -71.8%
|
2026-03-02 | $14,753,258MEGA | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
10b5-1 Sell
|
2026-02-26 | $617,303 | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Davidson Michael H.
• CEO
10b5-1 SellΔOwn -25.7%
2026-02-26
$5,562,671Whale
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
10b5-1 SellΔOwn -25.7%
|
2026-02-26 | $5,562,671Whale | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
10b5-1 Sell
|
2026-02-25 | $375,279 | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
10b5-1 Sell
|
2026-02-25 | $47,684 | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
10b5-1 Sell
|
2026-02-25 | $1,633,212Large | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
10b5-1 Sell
|
2026-02-24 | $115,250 | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Davidson Michael H.
• CEO
10b5-1 SellΔOwn -11.7%
2026-02-24
$2,223,693Large
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
10b5-1 SellΔOwn -11.7%
|
2026-02-24 | $2,223,693Large | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kastelein Johannes Jacob Pieter
• Officer • Chief Scientific Officer
Discretionary SellΔOwn -36.5%
2026-02-20
$1,091,778Large
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Scientific Officer
Discretionary SellΔOwn -36.5%
|
2026-02-20 | $1,091,778Large | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kastelein Johannes Jacob Pieter
• Officer • Chief Scientific Officer
Discretionary SellΔOwn -14.8%
2026-02-20
$514,220
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Scientific Officer
Discretionary SellΔOwn -14.8%
|
2026-02-20 | $514,220 | S | Form 4 |
|
NAMS
M
NewAmsterdam Pharma Co N.V.
Kooij Louise Frederika
• Officer • Chief Accounting Officer
Other
2026-01-28
$355,471
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Accounting Officer
Other
|
2026-01-28 | $355,471 | M | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kooij Louise Frederika
• Officer • Chief Accounting Officer
10b5-1 SellΔOwn -57.2%
2026-01-28
$1,037,062Large
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Accounting Officer
10b5-1 SellΔOwn -57.2%
|
2026-01-28 | $1,037,062Large | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kooij Louise Frederika
• Officer • Chief Accounting Officer
10b5-1 SellΔOwn -62.0%
2026-01-27
$1,298,798Large
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Accounting Officer
10b5-1 SellΔOwn -62.0%
|
2026-01-27 | $1,298,798Large | S | Form 4 |
|
NAMS
M
NewAmsterdam Pharma Co N.V.
Kooij Louise Frederika
• Officer • Chief Accounting Officer
Other
2026-01-27
$433,994
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Accounting Officer
Other
|
2026-01-27 | $433,994 | M | Form 4 |
|
NAMS
M
NewAmsterdam Pharma Co N.V.
Kooij Louise Frederika
• Officer • Chief Accounting Officer
Other
2026-01-26
$374,960
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Accounting Officer
Other
|
2026-01-26 | $374,960 | M | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kooij Louise Frederika
• Officer • Chief Accounting Officer
10b5-1 Sell
2026-01-26
$10,336
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Accounting Officer
10b5-1 Sell
|
2026-01-26 | $10,336 | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kooij Louise Frederika
• Officer • Chief Accounting Officer
10b5-1 SellΔOwn -58.0%
2026-01-26
$1,117,162Large
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Accounting Officer
10b5-1 SellΔOwn -58.0%
|
2026-01-26 | $1,117,162Large | S | Form 4 |
|
NAMS
M
NewAmsterdam Pharma Co N.V.
Kooij Louise Frederika
• Officer • Chief Accounting Officer
Other
2026-01-23
$416,075
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Accounting Officer
Other
|
2026-01-23 | $416,075 | M | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kooij Louise Frederika
• Officer • Chief Accounting Officer
10b5-1 SellΔOwn -34.4%
2026-01-23
$438,802
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Accounting Officer
10b5-1 SellΔOwn -34.4%
|
2026-01-23 | $438,802 | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Kooij Louise Frederika
• Officer • Chief Accounting Officer
10b5-1 SellΔOwn -40.6%
2026-01-23
$849,543
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Officer • Chief Accounting Officer
10b5-1 SellΔOwn -40.6%
|
2026-01-23 | $849,543 | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Somaiya Mayur Ian
• CFO
10b5-1 SellΔOwn -15.7%
2026-01-21
$512,782
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CFO
10b5-1 SellΔOwn -15.7%
|
2026-01-21 | $512,782 | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CFO
Other
|
2026-01-21 | $368,400 | M | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Somaiya Mayur Ian
• CFO
10b5-1 SellΔOwn -29.4%
2026-01-21
$823,436
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CFO
10b5-1 SellΔOwn -29.4%
|
2026-01-21 | $823,436 | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CFO
Other
|
2026-01-20 | $557,600 | M | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Somaiya Mayur Ian
• CFO
10b5-1 SellΔOwn -33.7%
2026-01-20
$1,262,047Large
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CFO
10b5-1 SellΔOwn -33.7%
|
2026-01-20 | $1,262,047Large | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CFO
10b5-1 Sell
|
2026-01-20 | $27,576 | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Somaiya Mayur Ian
• CFO
10b5-1 SellΔOwn -25.1%
2026-01-20
$634,778
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CFO
10b5-1 SellΔOwn -25.1%
|
2026-01-20 | $634,778 | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
Sell to Cover
|
2026-01-07 | $0 | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
Director
Discretionary Buy
|
2025-09-15 | $15,639 | P | Form 4 |